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Abstract
Background: Children with Down syndrome (DS) have an increased risk of childhood acute
leukemia, especially acute megakaryoblastic leukemia (AMKL) also called acute myeloid leukemia
(AML) type M7. Here four yet unreported infants with such malignancies are reported.
Results: An unbalanced translocation involving chromosome 1 was identified by GTG banding in
all cases. These were characterized in more detail by molecular cytogenetic approaches. Additional
molecular analysis revealed in three of the four cases mutations in exon 2 of the GATA binding
protein 1 (globin transcription factor 1), located in Xp11.23.
Conclusion: Our results corroborate that abnormalities of chromosome 1 are common in DS-
associated AMKL. Whether this chromosomal region contains gene(s) involved in hematopoietic
malignant transformation remains to be determined.
Background
Among congenital disorders, Down Syndrome (DS) is
one of the most common, affecting 1/800 – 1/1000 live
births. Children with DS have an increased risk of child-
hood acute leukemia (AL) when compared to the general
pediatric population under 4 years of age [1]. In DS the
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majority of leukemia diagnosed below the age of 2 years
is acute megakaryoblastic leukemia (AMKL) or acute mye-
loid leukemia (AML) type M7, according to the French-
American-British classification. This neonatal leukemia is
usually indistinguishable from other AL in clinical, cyto-
logical and immunophenotypical aspects. Nearly 25% of
infants that undergo remission after a transient leukemia
episode develop an AL 1–3 years later. Approximately
20% of infants with this malignancy progress to a sub-
type of AML-M7 or AMKL [2].
Several reports have now suggested that mutations in the
hematopoietic zinc-finger transcription factor gene
GATA1, which is essential for proper development of
erythroid cells, megakaryocytes, eosinophilis and mast
cells, could be an initiating event in DS leukemogenesis
[3,4]. Besides the involvement of GATA1, trisomy 21 is
strongly associated with leukemogenesis. Cytogenetic
analyses revealed other acquired recurrent abnormalities
associated with gain of chromosome 21. Recently, Fores-
tier and co-workers [5] analyzed 189 DS-associated AML
cases (DS-AML) and confirmed a distinct entity, originat-
ing from other genetic pathways than non-DS-AML.
Overall, children with DS are uniquely predisposed to
clonal disorders affecting the megakaryocyte lineage. At
birth, they can present hematopoiesis characterized by
pancytopenia and a myelodysplastic syndrome (MDS)
can be diagnosed. Some authors describe that this condi-
tion develops to TMD (= transient myeloid disorder) also
called transient leukemia (TL) [6]. Even though the pres-
ence of trisomy 21 and GATA1 mutations appear to be
sufficient for the excessive proliferation of megakaryob-
lasts seen in TMD, it seems to be insufficient for leukemo-
genesis because the majority of TMD resolve
spontaneously. The spontaneous disappearance of these
immature cells shortly after birth suggests that a specific
environment might be essential for the proliferation of
these cells. A hypothesis to explain this is that this exces-
sive proliferation of megakaryoblasts arises from the fetal
liver. The spontaneous regression of TMD shortly after
birth could then be explained by the loss of a permissive
fetal hematopoietic environment [6]. TMD and AMKL are
associated with trisomy 21 and mutations in GATA1.
However, it has been speculated that other additional
lesions result in explicitly leukemia. These additional
lesions could be mutations in P53, altered telomerase's
activity, or additional acquired karyotype abnormalities,
trisomy 8 being the most common in DS-AMKL [7-10].
Here four children with as DS-AML were studied for pres-
ence of mutations in GATA1, GTG banding and molecular
cytogenetic studies. Besides that 3/4 cases had a GATA1
mutation also 3 of them were associated with an unbal-
anced rearrangements of chromosome 1.
Case presentation
Between 2005 and 2006, four DS children with history of
MDS were referred to the cytogenetic department at Insti-
tuto Nacional de Câncer (INCa) of Rio de Janeiro, Brazil.
The clinical data, including outcome, as well as molecular
and (molecular) cytogenetic results are summarized in
Tab. 1.
The infants were 11 to 20 months old. In all four cases the
initial diagnosis was established by cell morphology, cyto-
chemistry and immunophenotyping analysis as standard-
ized procedures [11]. Criteria for AMKL diagnosis was the
presence of megakaryocyte-specific membrane markers
(CD41, CD42a, CD61) or CD36 positive bone marrow
(BM) fibrosis (Tab. 1). The diagnosis of MDS was estab-
lished previously in cases 2–4 according to the WHO cri-
teria, where one of the main distinguishing features of
these conditions is the proportion of blast cells in the
peripheral blood (PB) and/or BM as well as specific
cytogenetic alterations [12]. Case 1 was admitted with
AMKL but had been treated for five months with iron
orally, because of refractory anemia. The status of bone
marrow of the 4 cases was hyper-cellular, with high per-
centage of CD13, CD33, CD61 and CD41 positive blast
cells. As the diagnosis was AMKL/AML subtype M7
according to FAB classification [13] all four patients were
treated according to the AML BFM 98 protocol.
At present (September 2008), only 2 patients are alive and
in complete remission (cases 2 and 3). Patient with #1
died due to a relapse and #4 was in remission, but died of
bronchial aspiration.
Results and discussion
It is well known that DS-children are predisposed to
clonal disorders affecting the megakaryocyte lineage [6].
Also TMD and AMKL are associated with trisomy 21 and
GATA1 mutations. Table 1 summarizes each of our four
patient's data concerning clinic, (molecular) cytogenetics
and response to treatment.
GATA 1 mutation in exon 2 could not be detected for case
1, but were present in the other 3 cases (#2, #3, #4). These
findings are important to show the involvement of this
gene in our cases with DS-AMKL [3].
Chromosomal breakpoints detected in banding cytoge-
netics were confirmed and refined by molecular cytoge-
netics. Interestingly, three of the four cases (cases 1–3),
break-events took place in the chromosomal region 1q31
to 1q32. In case 4 also chromosome 1q was involved in a
rearrangement – here the breakpoint could not be refined
by molecular cytogenetics due to lack of material.
Recently, it has been shown that chromosomal aberra-
tions could provide important clues to the genetic eventsM
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Table 1: Clinical details and results obtained in the four studied cases
Case 1 Case 2 Case 3 Case 4
Clinical History persistent anemia since birth anemia, thrombocytopenia, MDS anemia, thrombocytopenia, MDS anemia, thrombocytopenia, MDS
Age of diagnosis 20 months 20 months 17 months 11 months
Sex/Ethnicity male/non-white female/white female/non-white male/non-white
Diagnosis August 2005 March 2006 February 2006 May 2005
BM Morphology Hyper-cellular, 72% blast cells, 
abnormal nucleoli and blebs
Hyper-cellular, 95% blast cells Hyper-cellular, 60% blast cells Hyper-cellular, 80% blast cells, 
nucleoli and blebs
WBC [ml] 3.8 × 103 13.0 × 106 4.0 × 106 36.7 × 106
Blast cells [%] 45 24 10 43
Platelets count [ml] 90 × 106 26.0 × 106 46 × 106 90 × 106
Final Diagnosis AML-M7 AML-M7 AML-M7 AML-M7
Immunophenotype CD33/CD13+; CD7/CD34/
CD117+; CD61/CD41+
CD61/CD14+/CD13/CD33+; 
CD38/CD117+
CD33/CD13+; CD7/CD34+; 
CD61+
CD33/CD13+; CD7/CD34/
CD117+; CD61/CD41+
Cytogenetics G banding 47,XY,der(19)t(1;19) 
(q24;p13.3),der(20)t(1;20) 
(q24;q11.2),+21c [13]
48,XX,t(1;16)(q21;q12.1), 
+der(16)t(9;16)(q13;q12.1), +21c 
[15]
47,XX,der(17)t(1;17) 
(q32;p13),+21c [20]
47,XY,-1, add(5)(p14), del(7)(p15), 
+der(7)t(1;7)(q21;p22), +21c [10]
MCB Banding 47,XY,der(19)t(1;19) 
(q31;p13.3),der(20)t(1;20) 
(q31;q12~13.1),r(20) 
(p11.2q12),+21c [53]/47,XY, 
der(2)t(2;11)(q37.3;q12~13), 
der(19)t(1;19)(q31;p13.3), 
der(20)t(1;20)(q31;q12~13.1),+21c[
5]
48,XX,t(1;16)(q31~32;q23), 
der(5)t(1;5)(q31~32;p13),+der(16)t(
16;1;5) (q23;q31~32;p13),+21c
47,XX,der(17)t(1;17) (q32;p13),+ 
21c
n.a.
Gata-1 status no mutation c.56G > A c.113 del G c.201A > G
Treatment AML BFM 98 AML BFM 98 AML BFM 98 AML BFM 98
Disease status Dead with disease Alive in complete remission Alive in complete remission Dead in complete remission
Clinical details and results obtained in the four studied AML-M7 with Down syndrome cases are given. Abbreviations: AML = acute myeloid leukemia; AML-M7: acute megakaryoblastic leukemia; 
BFM: Berlin-Frankfurt-München; BM = bone marrow; n.a. = not available due to lack of material; MDS = myelodysplastic syndrome; WBC: white blood cell count; MCB: multicolor bandingMolecular Cytogenetics 2009, 2:7 http://www.molecularcytogenetics.org/content/2/1/7
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associated with the transformation of a pre-leukemic, pos-
sibly GATA1 positive clone. The aberrations found for the
1q31~32 region, especially duplication, are in concord-
ance with previous reports of DS-AML with GATA1 muta-
tions [5]. Also partial duplications of 1q are reported as
typical, which we can confirm here for 3/4 cases. Addi-
tionally detected unbalanced rearrangements involved
chromosomes 2, 5, 7, 11, 16, 17 and 19, which were also
in concordance with previous reports on DS-AML.
Overall, our results, support evidence that genes located at
region 1q31 and 1q32 are responsible for secondary or
even primary mechanisms for the origin of AMKL in DS.
Further gene-hunting studies in this region have to be per-
formed to elucidate the pathogenetic mechanisms of the
long arm of chromosome 1 in DS-AML.
Methods
Cytogenetics
Banding cytogenetics
Karyotypes of BM cell were obtained at the time of AMKL
diagnosis for all four cases [See Figure 1]. Cytogenetic
analysis was performed as described [14]. Chromosomes
were identified and analyzed in concordance with [15].
Molecular cytogenetic analysis
To detect possible cryptic chromosomal changes multi-
plex fluorescence in situ hybridization (M-FISH) [16] and
(multitude) multicolor chromosome banding (mMCB),
MCB for chromosomes 1, 11, 17, 19 and 20 [17,18] were
applied [see Figure 2]. Additionally the following bacterial
artificial chromosome (BAC) probes were applied: RP11-
172J6 in 1q22, RP11-75C23 in 1q31, RP11-415M14 in
1q25, RP11-75C23 in 1q31 and RP11-031A5 in 5p12.
For-probe-labeling refer to [16,18]. Per case and probe
between 5 and 25 metaphases were analyzed, each.
Molecular genetic analysis
dHPLC (denaturating high performance liquid chroma-
tography) technique and direct sequencing were done to
detect and characterized possible GATA1 mutations [19].
Ethical approval
The Ethical Committee (Instituto Nacional de Câncer
(INCa) of Rio de Janeiro, Brazil) approved this study
(CONEP #12087).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MdSPdO, EMSdV and AMdS provided the bone marrow
samples of the 4 cases and their clinical history. MLMS,
AFdF, MTdS, EA, DRNG and ScR, did the cytogenetic work
up and analysis of the probes and the karyotype interpre-
tation. HM and TL did the FISH and further MCB-analysis.
All coauthors have been involved in drafting the manu-
script. EA, TL, MLMS and HM revised it critically for
important intellectual content.
Partial karyotypes presenting the aberrant cytogenetic banding results obtained in the four studied cases; the additional consti- tutional chromosomes 21 are not depicted Figure 1
Partial karyotypes presenting the aberrant cytogenetic banding results obtained in the four studied cases; the 
additional constitutional chromosomes 21 are not depicted. case 1: 
47,XY,der(19)t(1;19)(q24;p13.3),der(20)t(1;20)(q24;q11.2),+21c. case 2: 
48,XX,t(1;16)(q21;q12.1),+der(16)t(9;16)(q13;q12.1),+21c. case 3: 47,XX,der(17)t(1;17)(q32;p13),+21c. case 4: 47,XY,-
1,add(5)(p14),del(7)(p15),+der(7)t(1;7)(q21;p22),+21c.Molecular Cytogenetics 2009, 2:7 http://www.molecularcytogenetics.org/content/2/1/7
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FISH-results obtained in cases A, B and C after application of mMCB and MCB Figure 2
FISH-results obtained in cases A, B and C after application of mMCB and MCB. case A: MCB probe sets 1, 19 and 
20 showed the presence of two normal chromosomes 1, one normal chromosome 19 and no normal chromosome 20. Addi-
tionally a der(19)t(1;19)(q21;p13.3), a der(20)t(1;20)(q21;q11.2) and an r(20)(p11.2q12). A der(2)t(2;11) was described using 
MCB 11 and subtelomeric probe 2q (latter result not shown). case B: mMCB identified a reciprocal translocation 
t(1;16)(q31;q23) (red arrowhead), a der(5)(1;5)(q32;p13) (blue arrowhead), a der(16)t(16;1;5)(q23;q31~q32;p13) (green 
arrowhead) and the constitutional additional chromosome 21 (grey arrowhead). mMCB result is shown here in a three color 
channel depiction. case C: MCB using probe sets for chromosomes 1 and 17 confirmed the presence of a unbalanced translo-
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